Structural modifications of salicylates: Inhibitors of human CD81-receptor HCV-E2 interaction

Archiv der Pharmazie

Volumn 341, Issue 8, 2008, Pages 478-484

  Holzer, Marcel ^a   Ziegler, Sigrid ^a   Neugebauer, Alexander ^a   Kronenberger, Bernd ^a   Klein, Christian D ^a,b   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Benzyl salicylates; CD81 receptor; Hepatitis C virus; Large extracellular loop; Virtual screening

Indexed keywords

4 (QUINOLIN 3 YL)BENZYL 4 (PYRIMIDIN 5 YL)BENZOATE; 4 (QUINOLIN 3 YL)BENZYL 4 (QUINOLIN 3 YL)BENZOATE; 4 METHOXYBENZYL 4 (PYRIDIN 4 YL)BENZOATE; 4 METHOXYBENZYL 4 (PYRIMIDIN 5 YL)BENZOATE; 4 METHOXYPHENYL 4 (PYRIDIN 4 YL)BENZOATE; 4 METHOXYPHENYL 4 (PYRIMIDIN 5 YL)BENZOATE; BENZYL 2 HYDROXY 5 (PYRIDIN 3 YL)BENZOATE; BENZYL 4 (PYRIDIN 3 YL)BENZOATE; BENZYL 4 (PYRIDIN 4 YL)BENZOATE; BENZYL 4 (PYRIMIDIN 5 YL)BENZOATE; BENZYL 4 (QUINOLIN 3 YL)BENZOATE; BENZYL 4 (THIOPHEN 3 YL)BENZOATE; CD81 ANTBODY; CELL SURFACE PROTEIN; GLYCOPROTEIN E2; N BENZYL 4 (PYRIDIN 3 YL)BENZAMIDE; N BENZYL 4 (QUINOLIN 3 YL)BENZAMIDE; N BENZYL 4 (THIOPHEN 3 YL)BENZAMIDE; N PHENYL 4 (PYRIDIN 3 YL)BENZAMIDE; N PHENYL 4 (PYRIDIN 4 YL)BENZAMIDE; N PHENYL 4 (PYRIMIDIN 5 YL)BENZAMIDE; N PHENYL 4 (THIOPHEN 3 YL)BENZAMIDE; PHENYL 4 (PYRIDIN 3 YL)BENZOATE; PHENYL 4 (PYRIDIN 4 YL)BENZOATE; PHENYL 4 (PYRIMIDIN 5 YL)BENZOATE; PHENYL 4 (QUINOLIN 3 YL)BENZOATE; PHENYL 4 (THIOPHEN 3 YL)BENZOATE; SALICYLIC ACID BENZYL ESTER; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIVIRUS AGENT; CD81 ANTIGEN; GLYCOPROTEIN E2, HEPATITIS C VIRUS; LEUKOCYTE ANTIGEN; VIRUS ENVELOPE PROTEIN;

ARTICLE; BINDING AFFINITY; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; METABOLISM; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIGENS, CD; ANTIVIRAL AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HUMANS; PROTEIN BINDING; SALICYLATES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL ENVELOPE PROTEINS;

EID: 53149125181     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700261     Document Type: Article

References (17)

1. J. M. Pawlotsky, Trends Microbiol. 2004, 12, 96-102.
2. F. V. Chisari, Nature 2005, 436, 930-932.
3. K. Kitadokoro, M. Ponassi, G. Galli, R. Petracca, et al., Biol. Chem. 2002, 383, 1447-1452.
4. S. E. VanCompernolle, A. V. Wiznycia, J. R. Rush, M. Dhanasekaran, et al., Virology 2003, 314, 371-380.
5. A. Neugebauer, C. D. Klein, R. W. Hartmann, Bioorg. Med. Chem. Lett. 2004, 14, 1765-1769.
6. H. E. Drummer, K. A. Wilson, P. Poumbourios, J. Virol. 2002, 76, 11143-11147.
7. P. Pileri, Y. Uematsu, S. Campagnoli, G. Galli, Science 1998, 282, 938-941.
8. S. Ziegler, B. Kronenberger, S. Zeuzem, R. W. Hartmann, C. D. Klein, unpublished results, manuscript in preparation.
9. F. Francesco, M. Gianlorenzo, T. Aldo, J. Chem. Soc. 1970, 8, 1595-1598.
10. J. W. Guiles, S. G. Johnson, W. V. Murray, J. Org. Chem. 1996, 61, 5169-5171.
11. L. M. Gaster, H. K. Rami, P. A. Wyman (Smithkline Beecham PLC, UK), WO 9850358. 1998.
12. L. H. Sarett, W. C. Ruyle (Merck & Co, Inc), DE 1801303. 1967.
13. Y. Gong, H. W. Pauls, Syn. Lett. 2000, 6, 829831.
14. (Ciba Ltd), NL 6414307. 1965.
15. W. J. Coates, A. D. Rawlings (Smithkline Beecham PLC, UK) WO 9429277. 1994.
16. P. M. Carabateas, P. R. Brundage, K. O. Gelotte, M. D. Gruett, R. R. Lorenz, J. Heterocycl. Chem. 1984, 21, 1849-1856.
17. I. R. Baxendale, C. M. Griffiths-Jones, S. V. Ley, G. K. Tranmer, Chem. Eur. J. 2006, 12, 4407-4416.